Free Trial
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

$234.00
-0.94 (-0.40%)
(As of 06/12/2024 ET)
Today's Range
$233.15
$235.39
50-Day Range
$224.93
$246.17
52-Week Range
$224.00
$287.32
Volume
1.10 million shs
Average Volume
1.46 million shs
Market Capitalization
$67.63 billion
P/E Ratio
51.54
Dividend Yield
1.62%
Price Target
$280.17

Becton, Dickinson and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
19.7% Upside
$280.17 Price Target
Short Interest
Healthy
0.77% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.48
Upright™ Environmental Score
News Sentiment
0.84mentions of Becton, Dickinson and Company in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$2.10 M Sold Last Quarter
Proj. Earnings Growth
9.05%
From $13.04 to $14.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

111th out of 913 stocks

Surgical & Medical Instruments Industry

16th out of 100 stocks

BDX stock logo

About Becton, Dickinson and Company Stock (NYSE:BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

BDX Stock Price History

BDX Stock News Headlines

Piper Sandler Keeps Their Buy Rating on Becton Dickinson (BDX)
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/29 Dividend
3/07/2024
Dividend Payable
3/29/2024
Last Earnings
5/02/2024
Ex-Dividend for 6/28 Dividend
6/10/2024
Today
6/12/2024
Dividend Payable
6/28/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07588710
Employees
73,000
Year Founded
1897

Price Target and Rating

Average Stock Price Target
$280.17
High Stock Price Target
$312.00
Low Stock Price Target
$260.00
Potential Upside/Downside
+19.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$1.48 billion
Pretax Margin
8.34%

Debt

Sales & Book Value

Annual Sales
$19.37 billion
Cash Flow
$19.75 per share
Book Value
$88.92 per share

Miscellaneous

Free Float
288,110,000
Market Cap
$67.63 billion
Optionable
Optionable
Beta
0.44

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • Becton, Dickinson and Company has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company has a solid track record of innovation, particularly in the healthcare sector, which could lead to sustained competitive advantage.
  • With a current stock price of $250, Becton, Dickinson and Company's shares are attractively priced for potential investors looking for value.
  • The company has a healthy balance sheet with a low debt-to-equity ratio of 0.27, indicating financial stability.
  • Becton, Dickinson and Company has a history of rewarding shareholders through dividends, providing a source of passive income for investors.

Cons

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The healthcare sector is subject to regulatory risks and changes, which could impact Becton, Dickinson and Company's operations and profitability.
  • Intense competition in the healthcare industry may put pressure on the company's market share and margins.
  • Global economic uncertainties could affect demand for healthcare products and services, potentially impacting Becton, Dickinson and Company's revenue growth.
  • Fluctuations in raw material prices could impact the company's production costs and overall profitability.
  • Changes in healthcare policies and reimbursement rates could affect Becton, Dickinson and Company's financial performance and outlook.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

BDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Becton, Dickinson and Company stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BDX shares.
View BDX analyst ratings
or view top-rated stocks.

What is Becton, Dickinson and Company's stock price target for 2024?

6 equities research analysts have issued 12-month price objectives for Becton, Dickinson and Company's shares. Their BDX share price targets range from $260.00 to $312.00. On average, they predict the company's share price to reach $280.17 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts price targets for BDX
or view top-rated stocks among Wall Street analysts.

How have BDX shares performed in 2024?

Becton, Dickinson and Company's stock was trading at $243.83 on January 1st, 2024. Since then, BDX shares have decreased by 4.0% and is now trading at $234.00.
View the best growth stocks for 2024 here
.

Are investors shorting Becton, Dickinson and Company?

Becton, Dickinson and Company saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 2,230,000 shares, an increase of 13.2% from the May 15th total of 1,970,000 shares. Based on an average trading volume of 1,410,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.8% of the shares of the stock are sold short.
View Becton, Dickinson and Company's Short Interest
.

When is Becton, Dickinson and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our BDX earnings forecast
.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings results on Thursday, May, 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.20. The medical instruments supplier had revenue of $5.05 billion for the quarter, compared to analysts' expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a trailing twelve-month return on equity of 13.90%. The company's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.86 EPS.
Read the conference call transcript
.

How often does Becton, Dickinson and Company pay dividends? What is the dividend yield for Becton, Dickinson and Company?

Becton, Dickinson and Company declared a quarterly dividend on Tuesday, April 30th. Shareholders of record on Monday, June 10th will be given a dividend of $0.95 per share on Friday, June 28th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, June 10th.
Read our dividend analysis for BDX
.

Is Becton, Dickinson and Company a good dividend stock?

Becton, Dickinson and Company (NYSE:BDX) pays an annual dividend of $3.80 per share and currently has a dividend yield of 1.59%. The dividend payout ratio is 83.70%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, BDX will have a dividend payout ratio of 26.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BDX.

What guidance has Becton, Dickinson and Company issued on next quarter's earnings?

Becton, Dickinson and Company updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 12.950-13.150 for the period, compared to the consensus estimate of 12.950. The company issued revenue guidance of $20.1 billion-$20.3 billion, compared to the consensus revenue estimate of $20.3 billion.

What is Tom Polen's approval rating as Becton, Dickinson and Company's CEO?

136 employees have rated Becton, Dickinson and Company Chief Executive Officer Tom Polen on Glassdoor.com. Tom Polen has an approval rating of 91% among the company's employees. This puts Tom Polen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and Company investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Becton, Dickinson and Company's major shareholders?

Becton, Dickinson and Company's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.06%), Price T Rowe Associates Inc. MD (3.50%), Bank of New York Mellon Corp (1.41%), Clearbridge Investments LLC (1.00%), Mitsubishi UFJ Asset Management Co. Ltd. (0.88%) and Longview Partners Guernsey LTD (0.80%). Insiders that own company stock include Alexandre Conroy, Betty D Larson, Claire Fraser, David Hickey, James C Lim, Michael David Garrison, Rebecca W Rimel, Rebecca W Rimel, Richard Byrd, Roland Goette, Samrat S Khichi, Thomas E Polen Jr, Thomas J Spoerel and Thomas J Spoerel.
View institutional ownership trends
.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Becton, Dickinson and Company have any subsidiaries?
The following companies are subsidiares of Becton, Dickinson and Company: Accuri Cytometers, Accuri Cytometers Inc., Alverix Inc, Alverix Inc., Atto Bioscience Inc, BD Holding S. de R.L. de C.V., BD Infection Prevention BV, BD Kiestra BV, BD Kiestra Total Lab Automation, BD Rapid Diagnostic (Suzhou) Co. Ltd., BD San Luis Potosi S.A. de C.V., BD Switzerland Sarl, BD Ventures LLC, BD West Africa Limited, BDX INO LLC, Bard (Thailand) Limited, Bard ASDI Inc., Bard Access Systems Inc., Bard Acquisition Sub Inc., Bard Australia Pty. Limited, Bard Benelux N.V., Bard Brachytherapy Inc., Bard Brasil Indústria e Comércio de Produtos Para a Saúde Ltda., Bard Canada Inc., Bard Chile S.p.A., Bard Czech Republic s.r.o., Bard Devices Inc., Bard Dublin ITC Limited, Bard EMEA Finance Center Sp.z o.o., Bard European Distribution Center N.V., Bard Finance B.V. & Co. KG., Bard Financial Services Ltd., Bard Finland OY, Bard France S.A.S., Bard Global Holdings I LLC, Bard Global Holdings II LLC, Bard Global Holdings III LLC, Bard Healthcare Inc., Bard Healthcare Science (Shanghai) Limited, Bard Hellas S.A., Bard Holding SAS, Bard Holdings Limited, Bard Holdings Netherlands B.V., Bard Hong Kong Limited, Bard IP Holdings Inc., Bard India Healthcare Pvt. Ltd., Bard International Holdings B.V., Bard International Inc., Bard Istanbul Healthcare Limited Company, Bard Korea Ltd., Bard Limited, Bard MRL Acquisition Corp., Bard Malaysia Healthcare Sdn. Bhd., Bard Medica SA, Bard Medical Devices (Beijing) Co. Ltd., Bard Medical R&D (Shanghai) Co. Ltd., Bard Medical SA (Proprietary) Limited, Bard Mexico Realty S. de R.L. de C.V., Bard Norden AB, Bard Norway AS, Bard Pacific Health Care Company Ltd., Bard Peripheral Vascular Inc., Bard Poland Sp. z.o.o., Bard Productos Plasticos e Medicos Ltda., Bard Reynosa S.A. de C.V., Bard S.r.l., Bard Sdn. Bhd., Bard Shannon Limited, Bard Singapore Private Limited, Bard Sourcing Office Singapore Pte. Ltd., Bard Sweden AB, Bard UK Newco Limited, Bard de Espana S.A., Becton Dickinson (Gibraltar) Holdings Ltd., Becton Dickinson (Gibraltar) Limited, Becton Dickinson (Gibraltar) Management Limited, Becton Dickinson (Mauritius) Limited, Becton Dickinson (Pty) Ltd., Becton Dickinson (Thailand) Limited, Becton Dickinson A.G., Becton Dickinson A/S, Becton Dickinson Argentina S.R.L., Becton Dickinson Asia Holdings Ltd., Becton Dickinson Asia Limited, Becton Dickinson Austria GmbH, Becton Dickinson Austria Holdings GmbH, Becton Dickinson B.V., Becton Dickinson B.V. Saudi Limited Company, Becton Dickinson Benelux N.V., Becton Dickinson Biosciences Systems and Reagents Inc., Becton Dickinson Canada Inc., Becton Dickinson Caribe Ltd., Becton Dickinson Croatia d.o.o., Becton Dickinson Czechia s.r.o., Becton Dickinson Dispensing Belgium BVBA, Becton Dickinson Dispensing Denmark A/S, Becton Dickinson Dispensing France SAS, Becton Dickinson Dispensing Ireland Limited, Becton Dickinson Dispensing Norway, Becton Dickinson Dispensing Spain S.L.U., Becton Dickinson Dispensing UK Ltd., Becton Dickinson Distribution Center N.V., Becton Dickinson East Africa Ltd., Becton Dickinson Euro Finance Sarl, Becton Dickinson Europe Holdings S.A.S., Becton Dickinson France S.A.S., Becton Dickinson GSA Beteilgungs GmbH, Becton Dickinson Global Holdings I Inc., Becton Dickinson Global Holdings II LLC, Becton Dickinson Global Holdings IV LLC, Becton Dickinson Global Holdings V LLC, Becton Dickinson Global Holdings VII LLC, Becton Dickinson Global Holdings VIII LLC, Becton Dickinson Global Services Centre Sdn. Bhd, Becton Dickinson GmbH, Becton Dickinson Guatemala S.A., Becton Dickinson Hellas S.A., Becton Dickinson Holdings Limited, Becton Dickinson Holdings Ltd., Becton Dickinson Holdings Pte Ltd., Becton Dickinson Hungary Kft., Becton Dickinson India Private Limited, Becton Dickinson Industrias Cirurgicas Ltda., Becton Dickinson Infusion Therapy AB, Becton Dickinson Infusion Therapy Holdings UK Limited, Becton Dickinson Infusion Therapy Systems Inc., Becton Dickinson Infusion Therapy Systems Inc. S.A. de C.V., Becton Dickinson Infusion Therapy UK, Becton Dickinson Insulin Syringe Ltd., Becton Dickinson International Holdings II Pte Ltd., Becton Dickinson International Holdings III Pte Ltd., Becton Dickinson International Holdings Pte Ltd., Becton Dickinson Israel Ltd., Becton Dickinson Italia S.p.A., Becton Dickinson Ithalat Ihracat Limited Sirketi, Becton Dickinson Korea Holding Inc., Becton Dickinson Korea Ltd., Becton Dickinson Ltd., Becton Dickinson Luxembourg Finance S.a.r.L., Becton Dickinson Luxembourg Global Holdings Sarl, Becton Dickinson Luxembourg Holdings II S.a.r.L, Becton Dickinson Luxembourg Holdings III S.a.r.L, Becton Dickinson Luxembourg Holdings V S.a.r.L., Becton Dickinson Malaysia Inc., Becton Dickinson Management GmbH & Co. KG, Becton Dickinson Matrex Holdings Inc., Becton Dickinson Medical (S) Pte Ltd., Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Becton Dickinson Medical Devices (Suzhou) Co. Ltd., Becton Dickinson Medical Products Pte. Ltd., Becton Dickinson Medical Technology (Jiangsu) Co. Ltd., Becton Dickinson Netherlands Global Holdings II C.V., Becton Dickinson Netherlands Holdings B.V., Becton Dickinson Netherlands Holdings II B.V., Becton Dickinson Norway AS, Becton Dickinson O.Y., Becton Dickinson Overseas Services Ltd., Becton Dickinson Pakistan (Pvt) Ltd., Becton Dickinson Penel Limited, Becton Dickinson Philippines Inc., Becton Dickinson Polska Sp.z.o.o., Becton Dickinson Portugal Unipessoal Lda., Becton Dickinson Pty. Ltd., Becton Dickinson Research Centre Ireland Limited, Becton Dickinson Rowa Germany GmbH, Becton Dickinson Rowa Italy Srl, Becton Dickinson S.A., Becton Dickinson Sample Collection GmbH, Becton Dickinson Scot Financing L.L.P., Becton Dickinson Scot Financing L.P., Becton Dickinson Sdn. Bhd., Becton Dickinson Slovakia s.r.o., Becton Dickinson Sweden AB, Becton Dickinson Sweden Holdings AB, Becton Dickinson Switzerland Global Holdings SarL, Becton Dickinson Technology Campus India, Becton Dickinson U.K. Limited, Becton Dickinson UK Financing I Limited, Becton Dickinson UK Financing II Limited, Becton Dickinson Venezuela C.A., Becton Dickinson Venture LLC, Becton Dickinson Verwaltungs GmbH, Becton Dickinson Vostok LLC, Becton Dickinson Worldwide Investments Sa.r.L., Becton Dickinson Zambia Limited, Becton Dickinson and Company Ltd., Becton Dickinson de Colombia Ltda., Becton Dickinson de Mexico S.A. de C.V., Becton Dickinson del Uruguay S.A., Bee IT Solutions, Benex Ltd., Biometric Imaging, Bridger Biomed Inc., C. R. Bard (Portugal) - Produtos e Artigos Medicos e Farmaceuticos, C. R. Bard Do Brasil Productos Medicos Ltda., C. R. Bard GmbH, C. R. Bard Inc., C. R. Bard Netherlands Sales B.V., C.R. Bard Inc, CME America LLC, CME Ltd., CME Medical (UK) Limited, CME UK (Holdings) Limited, CRISI Medical Systems, CRISI Medical Systems Inc., Caesarea Medical Electronics, Cardal II LLC, Care Fusion Development Private Limited, CareFusion (Barbados) SrL, CareFusion (Shanghai) Commercial and Trading Co. Limited, CareFusion 213 LLC, CareFusion 2200 Inc., CareFusion 2201 Inc., CareFusion 302 LLC, CareFusion 303 Inc., CareFusion Asia (HK) Limited, CareFusion Corporation, CareFusion Corporation., CareFusion D.R. 203 Ltd., CareFusion France 309 S.A.S., CareFusion Israel 330 Ltd., CareFusion Italy 312 S.p.A., CareFusion Manufacturing LLC, CareFusion Mexico 215 S.A. de C.V., CareFusion Netherlands 328 B.V., CareFusion Netherlands 503 B.V., CareFusion Netherlands 504 B.V., CareFusion Netherlands Financing 283 C.V., CareFusion Resources LLC, CareFusion S.A. 319 (Proprietary) Limited, CareFusion Solutions LLC, CareFusion U.K. 244 Limited, CareFusion U.K. 305 Limited, CareFusion U.K. 306 Limited, Carmel Pharma AB, Carmel Pharma Inc, Cato Software Solutions, Cell Analysis Systems Inc, Cellular Research, Cellular Research Inc., Clearstream Technologies Group Limited, Clearstream Technologies Limited, Clontech Laboratories Inc, Corporativo BD de Mexico S. de R.L. de C.V., Critical Device Corporation, Cubex, Cytognos, Cytopeia Inc, DLD (Bermuda) Ltd., DVL Acquisition Sub Inc., Davol Inc., Davol International Limited, Davol Surgical Innovations S.A. de C.V., Difco Laboratories Incorporated, Distribuidora BD Mexico S.A. de C.V., Dutch American Manufacturers (D.A.M.) B.V., Dymax Corporation, Embo Medical Limited, Enturia de Mexico S. de R.L. de C.V., Enturican Inc., FJ International Inc., FlowCardia Inc., FlowCardia LLC, FlowJo LLC, Franklin Lakes Enterprises L.L.C., GSL Solutions, Gamer Lasertechnik GmbH, GenCell Biosystems, GenCell Biosystems Ltd., GeneOhm Sciences Canada ULC, GeneOhm Sciences Inc, Gentest Corporation, Gesco International Inc., Gesco International LLC, Glentech Inc, HandyLab Inc, HandyLab Inc., IBD Holdings LLC, Iontophoretics Corporation, JoHome LLC, Kabushiki Kaisha Medicon (Medicon Inc.), Liberator Health and Education Services Inc., Liberator Health and Wellness Inc., Liberator Medical Holdings Inc., Liberator Medical Supply Inc., Limited Liability Company Bard Rus, Loma Vista Medical Inc., Loma Vista Medical LLC, Luther Medical Products Inc, Lutonix Inc., Med-Design Corporation, Med-Design Investment Holdings Inc., Med-Safe Systems Inc, Med-Safe Systems Inc., MedChem Products Inc., Medafor Inc., Medegen LLC, Medinservice.com Inc., Medivance Inc., NAT Diagnostics Inc., NAT Diagnostics Inc., NOW Medical Distribution Inc., NOW Medical Distribution LLC, Navarre Biomedical LLC, Navarre Biomedical Ltd., Neomend Inc., Nippon Becton Dickinson Company Ltd., Omega Biosystems Incorporated, P.R.C. (Isialys) Societe a responsabilitie limitee, PT Becton Dickinson Indonesia, PharMingen, PharMingen., Plasso Technology Ltd, PreAnalytiX GmbH, Pristine Access Technologies Inc., ProSeed Inc., Procesos para Esterilizacion S.A. de C.V., Productos Bard de Mexico S.A. de C.V., Productos Para el Cuidado de la Salud S.A. de C.V., Puls Medical Devices AS LC, PureWick Corporation, Roberts Laboratories Inc., Rochester Medical Corporation, Rochester Medical Ltd., Saf-T-Med Inc, Safety Syringes Inc., Scanwell Health Inc., Sendal S.L.U., SenoRx Inc., SenoRx LLC, Shield Healthcare Centers Inc., Sirigen Group Limited, Sirigen II Limited, Sirigen Inc., Sistemas Médicos ALARIS S.A. de C.V., Specialized Cooperative Corporation, Specialized Health Products Inc., Specialized Health Products International Inc., Specialized Health Products International LLC, Staged Diabetes Management LLC, Straub Medical AG, Straub Medical AG, Surgical Site Solutions Inc., TVA Medical Inc, TVA Medical Inc., Tepha Inc, Tepha Inc., Tissuemed Ltd., Tri-County Medical & Ostomy Supplies Inc., TriPath Imaging Inc., Tru-Fit Marketing Corporation, Vas-Cath Incorporated, Vascular Pathways Inc., Velano Vascular, Velano Vascular Inc., Venclose Inc., Venetec International Inc., Venetec International LLC, Visitec, Y-Med Inc., Y-Med LLC, and ZebraSci Inc..
Read More
This page (NYSE:BDX) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners